As 2025 wraps up, the digital health world is resetting in a big way.
According to Rock Health’s latest Innovation Maturity Curve report, the industry has left the pandemic’s “quick-fix” phase behind. Healthtech is now in the thick of a fundamental rebuild.
And that’s not a speculation. Rock Health backs these conclusions with real data on venture funding patterns, research signals, and deal activity.
The report gives a grounded look on what’s taking off, what’s stagnating, and what may not survive the next cycle as we head into 2026.
The innovation maturity curve: What’s gaining momentum?
Rock Health’s Innovation Maturity Curve uses its unique system to track healthtech categories and rank innovations across four stages—Nascent, Emerging, Developing, and Mature.
This year’s curve shows some bets are paying off, some are maturing, and others are being forced to grow up fast.
Longevity gets real
One of the biggest shifts on the curve this year is Longevity officially moving into the Developing stage.
This category is no longer about supplements, wearables-for-the-wealthy, or vague anti-aging promises. Rock Health notes that longevity is increasingly taking shape as ongoing, longitudinal care.
The report points to companies like Function Health as a signal of this shift. Its $298 million Series B, valuing the company at $2.5 billion, is evidence that investors are backing platforms focused on continuous health baselines.
In other words: less “biohacking,” and more comprehensive, insurance-supported monitoring of metabolism and hormones, exactly what companies like Midi Health are banking on.
AI therapy bots find their footing
Purpose-built AI chatbots for mental health have also crossed an important threshold. Rock Health places them firmly in the Emerging category this year.
While general-purpose AI tools like ChatGPT still raise concerns around safety and reliability, mental health–specific AI platforms are beginning to break through.
Rock Health report cites Slingshot, which raised $93 million to build a psychology-trained AI model, as a key example. Even established players like Talkspace and Lyra are now using AI-driven tools to help patients stay engaged and supported between live therapy sessions.
Wearables level up: Beyond the wrist
Wearables have officially leveled up!
After sitting in Emerging territory last year, Rock Health now places wearables in the Developing stage. And the action has moved beyond the smartwatch.
The report highlights Oura as a defining example. Its smart ring fueled a $900 million raise and an $11 billion valuation, signaling that premium, clinically relevant wearables are now mainstream.
Another example is Apple’s move to integrate heart-rate sensors into AirPods.
These give a clear signal that biometric tracking is quietly becoming a part of everything we wear.
How the market is shaping: The “unlabeled” trend
Rock Health’s funding analysis shows an unevenly growing market. It isn’t a rising tide lifting all boats.
Instead, it’s a David-and-Goliath market, where capital is concentrating around scaled leaders rather than spreading evenly across the ecosystem.
The big picture:
Total funding for the year hit $9.9 billion through Q3, putting it ahead of 2024’s pace.
But that capital is concentrated in fewer, larger rounds.
The mega-deal comeback
Rock Health reports 19 deals over $100 million this year, led by companies like Abridge and Innovaccer.
The rise of the “unlabeled” deal
One of the most interesting signals in the report: 35% of financings were unlabeled. Meaning they didn’t fit neatly into Series A, B, or C.
What started as a pandemic stopgap has become a long-term strategy. Companies are taking smart money on their own terms, extending their runway without resetting their valuation in a tough market.
The squeeze in the middle
The Series B stage is getting brutally competitive. Deal flow there has dropped by nearly 50%, showing that the bar to prove you can truly scale has been raised dramatically.
2026 predictions: What is next for healthtech?
Based on these shifts, Rock Health outlines three Defining Currents that will shape digital health in 2026.
The rise of health benefits 2.0
Employer healthcare costs are at a 15-year high, and Rock Health suggests 2026 could be the tipping point.
The report predicts strong momentum for Alternative Benefit Models, including ICHRAs. Companies like Thatch and Venteur are positioned to benefit as employers move away from one-size-fits-all plans toward customizable benefit marketplaces. Where employees pick and choose their own coverage mix.
The translation layer becomes king
Collecting data is no longer the hard part.
Rock Health emphasizes that the real challenge for 2026 will be translating data into action. Turning a deluge of signals and information from wearables, diagnostics, and digital twins into decisions clinicians can actually use.
The industry’s focus is shifting from the initial “Wow” of new tech to the practical “How” of integrating it into real-world care. Success will hinge on making AI models reliable and actionable within the daily clinical workflow.
A regulatory reckoning
Rock Health report notes that policy is about to become a huge driver of change. The federal administration will reshape priorities.
For instance, environmental rollbacks slowed climate health innovation in 2025.
In 2026, attention will turn towards telehealth reimbursement and AI safety frameworks, including initiatives like VERA-MH.
Navigating this new regulatory landscape will be non-negotiable for every serious player.
Rock Health 2025 wrap-up: Final takeaway
The digital health market has recalibrated. The hype is gone; what remains is resilience.
As 2026 begins, Rock Health notes that the next phase of growth will be defined by durability. Success won’t come from bold vision alone, but from seamless integration into care pathways and measurable impact on patient outcomes.
That’s the new bar.
-By Alkama Sohail and the AHT Team
